Alvotech's Biosimilar Drug Faces FDA Setback Due to Manufacturing Issues
Alvotech receives FDA complete response letter for AVT05 biosimilar to Simponi, citing manufacturing facility deficiencies. Company revises 2025 revenue outlook downward.
/ 1 item
#ALVO↓